<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386616</url>
  </required_header>
  <id_info>
    <org_study_id>GA42469</org_study_id>
    <secondary_id>2020-002713-17</secondary_id>
    <nct_id>NCT04386616</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia</brief_title>
  <acronym>COVASTIL</acronym>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess
      the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A
      compared with placebo, in combination with standard of care (SOC), in patients hospitalized
      with severe coronavirus disease 2019 (COVID-19) pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">March 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recovery, Defined as the Time to a Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status</measure>
    <time_frame>From Baseline up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge or &quot;Ready for Discharge&quot;</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Alive and Free of Respiratory Failure</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status, Assessed Using a 7-Category Ordinal Scale</measure>
    <time_frame>Days 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-Free Days</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal of Care (Whichever Occurs First)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate at Days 14 and 28</measure>
    <time_frame>Days 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of â‰¤2 Maintained for 24 hours</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)</measure>
    <time_frame>Up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Respiratory Rate</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Pulse Rate</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Oxygen Saturation</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in RR, QRS, PR, QT, and QTcF Intervals, as Measured by Electrocardiogram (ECG)</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Heart Rate, as Measured by Electrocardiogram (ECG)</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Laboratory Test Abnormalities in Hematology Parameters</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinical Laboratory Test Abnormalities in Blood Chemistry Parameters</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of UTTR1147A at Specified Timepoints</measure>
    <time_frame>At predefined timepoints from Baseline until Study Completion (up to 60 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of MSTT1041A at Specified Timepoints</measure>
    <time_frame>At predefined timepoints from Baseline until Study Completion (up to 60 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study</measure>
    <time_frame>From Baseline up to 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>MSTT1041A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive MSTT1041A. Study treatment will be given in combination with standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSTT1041A-matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive MSTT1041A-matched placebo. Study treatment will be given in combination with standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UTTR1147A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive UTTR1147A. Study treatment will be given in combination with standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UTTR1147A-matched Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive UTTR1147A-matched placebo. Study treatment will be given in combination with standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSTT1041A</intervention_name>
    <description>Participants will receive up to 2 intravenous infusions of MSTT1041A.</description>
    <arm_group_label>MSTT1041A</arm_group_label>
    <other_name>Astegolimab</other_name>
    <other_name>RG6149</other_name>
    <other_name>RO7187807</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSTT1041A-matched Placebo</intervention_name>
    <description>Participants will receive up to 2 intravenous infusions of MSTT1041A-matched placebo.</description>
    <arm_group_label>MSTT1041A-matched Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UTTR1147A</intervention_name>
    <description>Participants will receive up to 2 intravenous infusions of UTTR1147A.</description>
    <arm_group_label>UTTR1147A</arm_group_label>
    <other_name>RG7880</other_name>
    <other_name>RO7021610</other_name>
    <other_name>IL-22Fc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UTTR1147A-matched Placebo</intervention_name>
    <description>Participants will receive up to 2 intravenous infusions of UTTR1147A-matched placebo.</description>
    <arm_group_label>UTTR1147A-matched Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive
             PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and
             evidenced by chest X-ray or CT scan

          -  Peripheral capillary oxygen saturation (SpO2) â‰¤93% (on room air or supplemental
             oxygen) or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) â‰¤300
             millimetres of mercury (mmHg) or requiring supplemental oxygen to maintain SpO2 &gt;93%
             or requirement for supplemental oxygen to maintain SpO2 at an acceptable level per
             local standard of care

        Exclusion Criteria:

          -  Pregnant or breastfeeding, or positive pregnancy test at screening

          -  Any serious medical condition or abnormality of clinical laboratory tests that, in the
             investigator's judgment, precludes the patient's safe participation in and completion
             of the study

          -  In the opinion of the investigator, progression to death is imminent and inevitable
             within the next 24 hours, irrespective of the provision of treatments

          -  Participating in another clinical drug trial

          -  Treatment with investigational therapy (other than for COVID-19) within 5 half-lives
             or 30 days (whichever is longer) prior to initiation of study drug

          -  Use of Janus kinase (JAK) inhibitor within 30 days or 5 drug elimination half-lives
             (whichever is longer) prior to screening

          -  Have received high-dose systemic corticosteroids (â‰¥1 mg/kg/day methylprednisolone or
             equivalent) within 72 hours prior to Day 1

          -  Known HIV infection with CD4 &lt;200 cells/microlitre (uL) or &lt;14% of all lymphocytes

          -  ALT or AST &gt;10 times the upper limit of normal (ULN) detected at screening

          -  History of anaplastic large-cell lymphoma or mantle-cell lymphoma

          -  History of cancer within the previous 5 years unless it has been adequately treated
             and considered cured or remission-free in the investigator's judgment

          -  Clinical evidence of active or unstable cardiovascular disease (e.g., acute myocardial
             ischemia or decompensated heart failure), as determined by investigator assessment,
             ECG, laboratory assessment, or echocardiographic data

          -  History of moderate or severe allergic, anaphylactic, or anaphylactoid reactions or
             hypersensitivity to any component of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GA42469 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arkansas For Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>eStudySite - Chula Vista - PPDS</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Medical Center - NAVREF</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Larkin Community Hospital Palm Springs Campus (Hialeah)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Larkin Community Hospital</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northside Hospital; Peachtree Dunwoody Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WellStar Research Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Louisiana Veterans Health Care System - NAVREF</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph'S Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical Mental Health Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center; Lewis M. Fraad Department of Pediatrics</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital; Department of Pharmacy</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cape Fear Valley Health System</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy St. Vincent Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center; Investigational Drug Services/Regional Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Temple Uni Medical Center; Pulmonary &amp; Critical Care Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkland Health &amp; Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23292</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro De Estudos Pesquisas em Molestias Infecciosas - CPCLIN</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital E Maternidade Celso Pierro PUCCAMP</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto</name>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alemao Oswaldo Cruz</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01323-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto do CoraÃ§Ã£o - HCFMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tijuana</name>
      <address>
        <city>Tijuana</city>
        <zip>22320</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

